Novel 20S proteasome inhibitors
Medizin
Ref.-Nr.: 0706-6249-IKF
Technology
Scientists from the Max-Planck-Institute for Terrestrial Microbiology have identified novel beta-lactone inhibitors from g-proteobacteria. The compounds specifically inhibit the eukaryotic 20S proteasome by covalently linking to subunit β5.
The compounds can be used
- in proteasome inhibitor therapies against cancer, infectious, inflammatory or autoimmune diseases
- as disinfection or sterilization agents of inanimate objects
- in plant protection or control of plant diseases.
We are now looking for a collaboration partner to further develop the compounds.
Patent Information
A PCT application was filed on November, 15th 2022: WO2023084124A1.
Publication
Yi-Ming Shi et al., Nature 2022. https://doi.org/10.1038/s41557-022-00923-2
PDF Download
- Ref.-Nr.: 0706-6249-IKF (371,6 KiB)
Kontaktperson
Dr. Ingrid Kapser-Fischer
Ernährungswissenschaftlerin, M.Sc.
Telefon: 089 / 29 09 19-19
E-Mail:
kapser-fischer@max-planck-innovation.de